Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis Non-Hodgkin's Lymphoma

NCT00141700 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00141700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis Non-Hodgkin's Lymphoma
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2003
Completion date
December 31, 2005
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin's